Positive Top-Line Results for Inhalable Parkinson ' s Treatment Positive Top-Line Results for Inhalable Parkinson ' s Treatment

The phase 3 SPAN-PD trial of CVT-301, an inhalable formulation of levodopa, met its primary endpoint of improved motor impairment vs placebo at 12 weeks, according to its manufacturer.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news